Skip to main content
. 2024 Oct 19;29(20):4949. doi: 10.3390/molecules29204949

Table 1.

Various nanoparticle systems for poorly soluble covalent drugs.

Entry Drug Nanoparticle Type Significant Findings Ref.
1 Orlistat PBA-hyaluronic acid nanoparticles 97% encapsulation efficiency (EE); 19% drug loading capacity (LC) [46]
2 Orlistat Hyaluronic acid–lipid–polymer hybrid nanoparticles 90% EE; 6% drug LC [47]
3 Orlistat PLGA-PEG nanoparticles 72% EE; 7% drug LC [48]
4 Orlistat Polydopamine-coated hollow capsules 91% EE (using Nile Red as proxy drug) [49]
5 Ibrutinib Pluronic-stabilised nanosuspension 21-fold increase in solubility [50]
6 Ibrutinib Pluronic-stabilised PLGA nanoparticles 4-fold enhancement of oral bioavailability [51]
7 Ibrutinib Cyclodextrin chitosan nanoparticles Inline graphic
77% EE; 13% drug LC
[52]